Tytuł pozycji:
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
-
Tytuł:
-
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
-
Autorzy:
-
Yamamoto, N. (AUTHOR)
Seto, T. (AUTHOR)
Nishio, M. (AUTHOR)
Goto, K. (AUTHOR)
Okamoto, I. (AUTHOR)
Yamanaka, T. (AUTHOR)
Tanaka, M. (AUTHOR)
Takahashi, K. (AUTHOR)
Fukuoka, M. (AUTHOR)
-
Źródło:
-
Lung Cancer (01695002). Jan2021, Vol. 151, p20-24. 5p.
-